Tuberculosis and Malaria are two major global threats both account 5 million deaths annually (mostly in poor countries). Despite the worldwide ravages of Tuberculosis and Malaria, chemotherapeutic regimens against these two diseases have remained largely unchanged. There is an urgent need to develop novel, effective, and affordable drugs to treat both diseases because resistance has developed or is developing to existing therapy. Scientists around the world are seeking new ways to combat the two opportunistic pathogens.
Mycobacterium tuberculosis and Plasmodium Falciparum responsible both organisms share enzymatic components of the type II fatty acid biosynthetic pathway (FAS-II). Enoyl acyl carrier protein reductase (ENR), is one of the key type II enzyme, has been repeatedly validated as an effective antimicrobial target (eg INH, diazoborines , triclosan , and thiolactomycin)
Triclosan, the ENR inhibitor showed very good activity against both organisms. Targeting ENR with new class of compounds may yield new Drug for the use against these devastating pathogens